Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.68 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.68 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.68 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.63 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.63 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.59 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4319312 | 1.00 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL28333157 | 1.00 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL14253668 | 1.00 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1620410 | 1.00 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL30586905 | 1.00 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16349344 | 1.00 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4314027 | 1.00 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL11324902 | 0.91 | P2RY2 (0.67) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL7034697 | 0.91 | P2RY6 (0.67) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL7034690 | 0.91 | P2RY6 (0.67) | P2RY2P2RY6P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333730-A1 | SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF | SHANGHAI JUNSHI BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | claimed |
| US-20250250573-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-08-07 | — | — | US | claimed |
| EP-4594484-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| EP-4569113-A1 | 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-06-18 | — | — | EP | claimed |
| EP-4569114-A2 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| EP-4568682-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| US-20250188464-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-06-12 | — | — | US | claimed |
| US-20250188465-A1 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-06-12 | — | — | US | claimed |
| CN-120077134-A | APOC 3-targeted polynucleic acid molecule and application thereof | 靖因药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| US-10829763-B2 | TMPRSS6 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-11-10 | — | — | US | claimed |
| US-10478500-B2 | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | claimed |
| US-10246713-B2 | TMPRSS6 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | claimed |
| EP-1501938-B1 | ANALYSIS OF SUBSTRATE UTILIZATION BY ANIMAL OR PLANT CELLS | BIOLOG INC (US) | 2009-10-21 | — | — | EP | claimed |
| EP-1501938-A4 | COMPARATIVE PHENOTYPE ANALYSIS OF CELLS, INCLUDING TESTING OF BIOLOGICALLY ACTIVE COMPOUNDS | BIOLOG INC (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1501938-A2 | COMPARATIVE PHENOTYPE ANALYSIS OF CELLS, INCLUDING TESTING OF BIOLOGICALLY ACTIVE COMPOUNDS | BIOLOG, INC. (US) | 2005-02-02 | — | — | EP | claimed |
| US-6727076-B2 | UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES | BIOLOG, INC. | 2004-04-27 | — | — | US | claimed |
| WO-2003089652-A2 | COMPARATIVE PHENOTYPE ANALYSIS OF CELLS, INCLUDING TESTING OF BIOLOGICALLY ACTIVE COMPOUNDS | BIOLOG, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030162164-A1 | Comparative phenotype analysis of cells, including testing of biologically active compounds | BIOLOG, INC. | 2003-08-28 | — | — | US | claimed |
| US-6472201-B1 | GROWING AND TESTING MICROORGANISMS IN A MULTITEST FORMAT WHICH UTILIZES A GEL FORMING MATRIX FOR THE RAPID SCREENING OF CLINICAL AND ENVIRONMENTAL CULTURES | BIOLOG, INC. | 2002-10-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829763-B2 | TMPRSS6 iRNA compositions and methods of use thereof | TMPRSS6, RNASE1, TFRC | SLC28A1 1968/4885SLC28A2 1976/4885SLC29A1 1232/4885 |
| US-10478500-B2 | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression | HAO1, HAO2, ACOX1 | SLC28A1 866/4885SLC28A2 1677/4885SLC29A1 992/4885 |
| US-20250333730-A1 | SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF | TEK, TIE1, PCSK9 | SLC28A1 2434/4885SLC28A2 2780/4885SLC29A1 2787/4885 |
| US-20250188464-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LPL, LDLR, PNLIP | SLC28A1 332/4885SLC28A2 289/4885SLC29A1 549/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | SLC28A1 2343/4885SLC28A2 2401/4885SLC29A1 1381/4885 |
| US-10246713-B2 | TMPRSS6 iRNA compositions and methods of use thereof | TMPRSS6, RNASE1, TFRC | SLC28A1 1968/4885SLC28A2 1976/4885SLC29A1 1232/4885 |
| US-20250250573-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | F13B, F13A1, F12 | SLC28A1 1343/4885SLC28A2 1014/4885SLC29A1 1472/4885 |
| US-20250188465-A1 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | APOB, APOL1, NOP10 | SLC28A1 1683/4885SLC28A2 1295/4885SLC29A1 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.